• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新诊断的帕金森病患者运动障碍、残疾和生活质量的预后因素。

Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD.

机构信息

Department of Neurology, University of Amsterdam, The Netherlands.

出版信息

Neurology. 2013 Feb 12;80(7):627-33. doi: 10.1212/WNL.0b013e318281cc99. Epub 2013 Jan 23.

DOI:10.1212/WNL.0b013e318281cc99
PMID:23345637
Abstract

OBJECTIVE

In Parkinson disease (PD), the rate of clinical progression is highly variable. To date, there are conflicting findings concerning the prognostic factors influencing the rate of progression. Methodologic issues such as the use of selected patients from therapeutic trials, and short durations of follow-up probably underlie this problem. We therefore designed a prospective follow-up study of a cohort of newly diagnosed patients with PD.

METHODS

A cohort of 129 patients with newly diagnosed PD was assessed at baseline, and 1, 2, 3, and 5 years later. The rate of progression and its prognostic factors on the level of motor impairments, disability, and quality of life were investigated using linear mixed-model analysis.

RESULTS

Annual increase of motor impairments measured with the Unified Parkinson's Disease Rating Scale-Motor Examination was estimated to be 2.46 points (95% confidence interval: 2.05-2.88). The main determinants of faster increase of motor impairments were male sex and cognitive dysfunction at the time of diagnosis. The main determinants of faster increase of disability were higher age at onset, cognitive dysfunction, and the presence of levodopa-nonresponsive motor symptoms at the time of diagnosis. No clinically relevant determinants were found for the decrease in quality of life.

CONCLUSION

This study shows the importance of nondopaminergic symptoms at the time of diagnosis, because these symptoms are the main determinants of increased disability in the first 5 years of the disease.

摘要

目的

在帕金森病(PD)中,临床进展的速度高度可变。迄今为止,关于影响进展速度的预后因素存在相互矛盾的发现。方法学问题,如从治疗试验中选择特定患者,以及随访时间短,可能是造成这一问题的原因。因此,我们设计了一项新诊断 PD 患者队列的前瞻性随访研究。

方法

对 129 例新诊断为 PD 的患者进行了队列评估,基线时评估一次,然后在 1、2、3 和 5 年后各评估一次。使用线性混合模型分析,研究了运动障碍、残疾和生活质量水平上的进展速度及其预后因素。

结果

使用统一帕金森病评定量表-运动检查评估的运动障碍的年增长率估计为 2.46 分(95%置信区间:2.05-2.88)。运动障碍更快进展的主要决定因素是男性和诊断时的认知功能障碍。残疾更快进展的主要决定因素是发病年龄较高、认知功能障碍以及诊断时存在对左旋多巴反应不佳的运动症状。生活质量下降没有发现具有临床意义的决定因素。

结论

本研究表明诊断时非多巴胺能症状的重要性,因为这些症状是疾病前 5 年残疾增加的主要决定因素。

相似文献

1
Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD.新诊断的帕金森病患者运动障碍、残疾和生活质量的预后因素。
Neurology. 2013 Feb 12;80(7):627-33. doi: 10.1212/WNL.0b013e318281cc99. Epub 2013 Jan 23.
2
Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease.新发帕金森病患者运动障碍、残疾和生活质量的进展和预后因素。
Mov Disord. 2011 Feb 15;26(3):449-56. doi: 10.1002/mds.23467. Epub 2011 Feb 10.
3
Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.晚期帕金森病患者的空肠内左旋多巴输注:对运动和非运动症状的长期影响及其对患者和照料者生活质量的影响。
Eur Rev Med Pharmacol Sci. 2012 Jan;16(1):79-89.
4
Determinants of disability and quality of life in mild to moderate Parkinson disease.轻度至中度帕金森病患者残疾及生活质量的决定因素
Neurology. 2008 Jun 3;70(23):2241-7. doi: 10.1212/01.wnl.0000313835.33830.80.
5
Progression of motor impairment and disability in Parkinson disease: a population-based study.帕金森病运动功能障碍和残疾的进展:一项基于人群的研究。
Neurology. 2005 Nov 8;65(9):1436-41. doi: 10.1212/01.wnl.0000183359.50822.f2.
6
Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.普拉克索与左旋多巴起始治疗对早期帕金森病的长期影响。
Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.
7
How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder.帕金森病如何开始?特发性 REM 睡眠行为障碍的前驱期帕金森病运动变化。
Brain. 2012 Jun;135(Pt 6):1860-70. doi: 10.1093/brain/aws093. Epub 2012 May 4.
8
Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.帕金森病空肠内左旋多巴输注:一项关于对非运动症状和生活质量影响的多中心试点研究
Mov Disord. 2009 Jul 30;24(10):1468-74. doi: 10.1002/mds.22596.
9
[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].[司来吉兰在日常临床应用中。帕金森病患者联合治疗的研究结果]
Fortschr Neurol Psychiatr. 2008 Oct;76(10):594-9. doi: 10.1055/s-2008-1038249. Epub 2008 Oct 2.
10
What factors influence motor complications in Parkinson disease?: a 10-year prospective study.帕金森病运动并发症的影响因素有哪些?一项为期10年的前瞻性研究。
Clin Neuropharmacol. 2012 Jan-Feb;35(1):1-5. doi: 10.1097/WNF.0b013e31823dec73.

引用本文的文献

1
Rate of motor progression in Parkinson's disease: a systematic review and meta-analysis.帕金森病运动进展率:一项系统评价与荟萃分析
Front Neurol. 2024 Sep 26;15:1452741. doi: 10.3389/fneur.2024.1452741. eCollection 2024.
2
Motor progression trajectories and risk of mild cognitive impairment in Parkinson's disease: A latent class trajectory model from PPMI cohort.帕金森病患者运动进展轨迹与轻度认知障碍风险:来自 PPMI 队列的潜在类别轨迹模型。
CNS Neurosci Ther. 2024 Aug;30(8):e14918. doi: 10.1111/cns.14918.
3
Changes in the correlation between substantia nigra hyperechogenicity area and Parkinson's disease severity at different Hoehn and Yahr stages.
黑质高回声面积与不同 Hoehn 和 Yahr 分期帕金森病严重程度相关性的变化。
Neurol Sci. 2024 Dec;45(12):5739-5747. doi: 10.1007/s10072-024-07697-0. Epub 2024 Aug 2.
4
Mobile Applications for Resting Tremor Assessment in Parkinson's Disease: A Systematic Review.用于帕金森病静止性震颤评估的移动应用程序:一项系统综述
J Clin Med. 2023 Mar 16;12(6):2334. doi: 10.3390/jcm12062334.
5
A progression analysis of motor features in Parkinson's disease based on the mapper algorithm.基于映射器算法的帕金森病运动特征进展分析。
Front Aging Neurosci. 2023 Feb 21;15:1047017. doi: 10.3389/fnagi.2023.1047017. eCollection 2023.
6
Potential Link Between Cognition and Motor Reserve in Patients With Parkinson's Disease.帕金森病患者认知与运动储备之间的潜在联系。
J Mov Disord. 2022 Sep;15(3):249-257. doi: 10.14802/jmd.22063. Epub 2022 Sep 7.
7
Levodopa responsiveness in Parkinson's disease: harnessing real-life experience with machine-learning analysis.左旋多巴对帕金森病的反应性:利用真实经验与机器学习分析。
J Neural Transm (Vienna). 2022 Oct;129(10):1289-1297. doi: 10.1007/s00702-022-02540-2. Epub 2022 Aug 27.
8
COMT Inhibitors in the Management of Parkinson's Disease.儿茶酚-O-甲基转移酶抑制剂在帕金森病治疗中的应用
CNS Drugs. 2022 Mar;36(3):261-282. doi: 10.1007/s40263-021-00888-9. Epub 2022 Feb 25.
9
Predictors of clinically significant quality of life impairment in Parkinson's disease.帕金森病中具有临床意义的生活质量受损的预测因素。
NPJ Parkinsons Dis. 2021 Dec 16;7(1):118. doi: 10.1038/s41531-021-00256-w.
10
Determinants of quality of life in Parkinson's disease: a perspective of novel clinical subtypes.帕金森病生活质量的决定因素:新型临床亚型视角。
Ann Clin Transl Neurol. 2021 Nov;8(11):2174-2183. doi: 10.1002/acn3.51475. Epub 2021 Oct 30.